CClinicalTrials.gg
CompletedNCT03255148Updated Aug 1, 2019

Influence of Oxytocin on Resting State Neurophysiological Measures

A Phase 1 interventional study of Oxytocin and Placebo in Oxytocin, sponsored by KU Leuven. Completed at 1 site in Belgium. Open to male participants aged 18 Years to 38 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-01.

Sponsored by KU Leuven · Phase 1, Interventional, and Basic science

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 38 Years
Sex
Male
01

Study summary

In this study, the investigators will explore the influence of oxytocin administration on several neurophysiological responses (EEG, skin conductance and heart rate) during rest.

Read the detailed description

Oxytocin is known to influence several neurophysiological measures, such as heart rate, EEG and skin conductance during specific tasks (e.g., emotion recognition, fear learning and extinction). However, not much is known about the influence of oxytocin on those measures during rest. Therefore, in this randomized, placebo controlled, double blinded study, the investigators will investigate the influence of oxytocin during a resting period of 5 minutes. Heart rate, skin conductance, respiration and EEG will be measured before and after oxytocin or placebo administration. The investigators expect that oxytocin will increase the heart rate variability and decrease the skin conductance levels. Exploratory, the investigators will conduct a cross-frequency analysis of band power and asses the relationship between distinct indexes of sympathetic / parasympathetic balance.

Please note that this study is part of a larger study in which the investigators also asses the influence of oxytocin on neurophysiological responses elicited by direct gaze

02

Conditions studied

  • Oxytocin

Keywords

  • resting state
  • EEG
  • skin conductance
  • heart rate
  • oxytocin
03

Who can participate

Ages eligible
18 Years to 38 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • right-handed
  • male
  • age between 18 and 35
  • Normal or adjusted-to-normal vision (with lenses only)
  • Dutch as mother tongue

Exclusion criteria

Exclusion Criteria:

  • not right-handed
  • female
  • age below 18 or above 35
  • Need to wear glasses
  • Dutch not as mother tongue
04

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Oxytocin

    Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)

    Drug: Oxytocin

  • Placebo comparator
    Placebo

    saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)

    Drug: Placebo

Interventions

  • DrugOxytocin

    Syntocinon nasal spray

    Also known as: syntocinon

  • DrugPlacebo

    Placebo nasal spray

05

What researchers measure

Primary outcomes

  1. Change in heart rate variability after oxytocin administration

    The influence of oxytocin administration on heart rate variability

    Time frame: Assessment over 5 minutes, before and after oxytocin or placebo administration

Secondary outcomes

  1. Change in skin conductance level after oxytocin administration

    The influence of oxytocin administration on skin conductance level

    Time frame: Assessment over 5 minutes, before and after oxytocin or placebo administration

06

Study locations

1 site
  • KU Leuven
    Leuven, 3000, Belgium
07

Registry details

Key details

Study ID
NCT03255148
Lead sponsor
KU Leuven
Collaborators
Research Foundation Flanders
Responsible party
Kaat Alaerts (Prof. Dr. Kaat Alaerts, KU Leuven) — Principal investigator
First posted
Aug 21, 2017
Start date
Jul 24, 2017
Primary completion
May 18, 2018
Completion
May 18, 2018
Last update
Aug 1, 2019

Study contacts

Kaat Alaerts, PhD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion